The evolution of medical knowledge and the release of tighter regulatory guidelines demand more and more intensive controls of cardiac data to guarantee drugs safety, and notably :   assessing the ECG evolution of patients when under a new drug, quickly receiving alerts in case of severe ECG abnormalities, storing all the ECGs of a patient and tracking (comparing) any changes over time.

CardiaBase provides interpretations which are based on reading methods that are:   reproducible, standardized, highly accurate, performed by trained cardiologists. The central reading of ECGs make it possible to:   increase study relevance and interpretation accuracy, reduce the number of patients included, perform comparative analysis to assess the side effects and/or ECG changes over time. CardiaBase is developing a network of partner Phase I Units. If you want to know more about this program, contact us.